Free Trial
NASDAQ:TRML

Tourmaline Bio (TRML) Stock Price, News & Analysis

Tourmaline Bio logo
$16.77 +0.59 (+3.61%)
Closing price 03:43 PM Eastern
Extended Trading
$16.82 +0.04 (+0.24%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tourmaline Bio Stock (NASDAQ:TRML)

Key Stats

Today's Range
$16.11
$16.52
50-Day Range
$14.54
$19.90
52-Week Range
$11.56
$29.79
Volume
59,085 shs
Average Volume
255,266 shs
Market Capitalization
$430.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33
Consensus Rating
Buy

Company Overview

Tourmaline Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

TRML MarketRank™: 

Tourmaline Bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 615th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tourmaline Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tourmaline Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tourmaline Bio is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tourmaline Bio is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tourmaline Bio has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tourmaline Bio's valuation and earnings.
  • Percentage of Shares Shorted

    17.78% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Tourmaline Bio does not currently pay a dividend.

  • Dividend Growth

    Tourmaline Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.78% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    2 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tourmaline Bio's insider trading history.
Receive TRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter.

TRML Stock News Headlines

Tourmaline Bio Inc News (TRML) - Investing.com
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
See More Headlines

TRML Stock Analysis - Frequently Asked Questions

Tourmaline Bio's stock was trading at $20.28 at the beginning of the year. Since then, TRML shares have decreased by 17.3% and is now trading at $16.7750.

Tourmaline Bio, Inc. (NASDAQ:TRML) released its quarterly earnings results on Friday, May, 2nd. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/02/2025
Today
7/03/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRML
Previous Symbol
NASDAQ:TRML
Web
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.33
High Stock Price Target
$70.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+200.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.21 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$11.71 per share
Price / Book
1.40

Miscellaneous

Free Float
22,346,000
Market Cap
$421.79 million
Optionable
Optionable
Beta
2.00
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:TRML) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners